CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib

Journal of Cancer Research and Therapeutics

Volumn 8, Issue 2, 2012, Pages 247-253

  Il Na, Im ^a   Choe, Du Hwan ^a   Kim, Cheol Hyeon ^a   Park, Sun Hoo ^a   Park, Jong Heon ^a   Lee, Jae Cheol ^b  

^a Korea Cancer Center Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Epidermal growth factor receptor; erlotinib; gefitinib; mutation; non small cell lung cancer; stage

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE MUTATION; GENOTYPE; HAZARD RATIO; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; QUINAZOLINES; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84864697468     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.98979     Document Type: Article

References (27)

1. Lee CT. Epidemiology of Lung Cancer in Korea. Cancer Res Treat 2002;34:3-7.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
4. Wang T, Nelson RA, Bogardus A, Grannis FW Jr. Five-year lung cancer survival: Which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 2010;116:1518-25.
5. Park J, Park BB, Kim JY, Lee SH, Lee SI, Kim HY, et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 2004;10:4383-8.
6. Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K, Fukuoka M. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 2004;46:247-54.
7. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated withgefitinib. J Clin Oncol 2006;24:2549-56.
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. Engl J Med 2005;353:123-32.
9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
10. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
11. Dacic S. EGFR assays in lung cancer. Adv Anat Pathol 2008;15:241-7.
12. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
13. Verschakelen JA, De Wever W, Bogaert J. Role of computed tomography in lung cancer staging. Curr Opin Pulm Med 2004;10:248-55.
14. Yano M, Sasaki H, Kobayashi Y, Yukiue H, Haneda H, Suzuki E, et al. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol 2006;1:413-6.
15. Laack E, Simon R, Regier M, Andritzky B, Tennstedt P, Habermann C, et al. Miliary never-smoking adenocarcinoma of the lung: Strong association with epidermal growth factor receptor exon 19 deletion. J Thorac Oncol 2011;6:199-202.
16. Na II, Park JH, Choe DH, Lee JK, Koh JS. Association of Epidermal Growth Factor Receptor Mutations with Metastatic Presentation in Non-small Cell Lung Cancer. ISRN Oncol 2011;2011:756265.
17. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136:260-71.
18. Na II, Lee TH, Choe DH, Cheon GJ, Kim CH, Koh JS, et al. A diagnostic model to detect silent brain metastases in patients with non-small cell lung cancer. Eur J Cancer 2008;44:2411-7.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
20. Na II, Kang HJ, Cho SY, Koh JS, Lee JK, Lee BC, et al. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. Eur J Cancer 2007;43:520-6.
21. Boldrini L, Gisfredi S, Ursino S, Camacci T, Baldini E, Melfi F, Fontanini G. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: A sensitive method for molecular diagnosis. J Thorac Oncol 2007;2:1086-90.
22. Togashi Y, Masago K, Kubo T, Sakamori Y, Kim YH, Hatachi Y, et al. Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. Cancer 2011;117:819-25.
23. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: Prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011-9.
24. Mellstedt H. Cancer initiatives in developing countries. Ann Oncol 2006;17 Suppl 8:viii24-31.
25. Kanavos P. The rising burden of cancer in the developing world. Ann Oncol 2006;17 Suppl 8:viii15-23.
26. William WN Jr, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting stage IIIB and IV non-small cell lung cancer: Analysis of the surveillance, epidemiology, and end results data. Chest 2009;136: 701-9.
27. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7.